Guizhou Yibai Pharmaceutical Co., Ltd.

XSSC:600594 Stock Report

Market Cap: CN¥2.5b

Guizhou Yibai Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Guizhou Yibai Pharmaceutical has been growing earnings at an average annual rate of 12.2%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 5.9% per year.

Key information

12.2%

Earnings growth rate

12.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-5.9%
Return on equity-0.7%
Net Margin-0.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guizhou Yibai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSSC:600594 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 242,709-91,589112
31 Dec 232,8211031,587112
30 Sep 232,773-4531,509122
30 Jun 232,769-4251,516123
31 Mar 232,731-4331,497129
31 Dec 222,735-4261,533127
30 Sep 222,8401431,628125
30 Jun 223,1062001,801125
31 Mar 223,2102231,871128
31 Dec 213,3472441,986136
30 Sep 213,5863352,075153
30 Jun 213,6272792,153149
31 Mar 213,5512402,110165
31 Dec 203,4132292,043146
30 Sep 203,2861762,04389
30 Jun 203,2251612,073106
31 Mar 203,2241432,092108
31 Dec 193,3611422,164119
30 Sep 193,480-7652,291132
30 Jun 193,599-7892,265122
31 Mar 193,744-7682,33485
31 Dec 183,883-7252,36377
30 Sep 183,8452682,29299
30 Jun 183,7483702,154100
31 Mar 183,8413882,22883
31 Dec 173,8083882,19771
30 Sep 173,8774112,17730
30 Jun 173,9133962,2650
31 Mar 173,8814032,2520
31 Dec 163,6873852,2050
30 Sep 163,5193172,2650
30 Jun 163,4393022,2780
31 Mar 163,3642142,3590
31 Dec 153,3031892,3330
30 Sep 153,5323322,3790
30 Jun 153,4963722,3200
31 Mar 153,2234822,0080
31 Dec 143,1574781,9800
30 Sep 143,1204831,9410
30 Jun 143,0014631,8440
31 Mar 142,8864411,7810
31 Dec 132,7854291,7090
30 Sep 132,5143811,5650
30 Jun 132,3413561,4310

Quality Earnings: 600594 is currently unprofitable.

Growing Profit Margin: 600594 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600594 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.2% per year.

Accelerating Growth: Unable to compare 600594's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 600594 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).


Return on Equity

High ROE: 600594 has a negative Return on Equity (-0.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.